For the quarter ended December 2024, Illumina (ILMN) reported income of $1.1 billion, down 1.6% over the identical interval final yr. EPS got here in at $0.86, in comparison with $0.14 within the year-ago quarter.
The reported income represents a shock of +2.64% over the Zacks Consensus Estimate of $1.08 billion. With the consensus EPS estimate being $0.92, the EPS shock was -6.52%.
Whereas buyers carefully watch year-over-year modifications in headline numbers — income and earnings — and the way they evaluate to Wall Road expectations to find out their subsequent plan of action, some key metrics all the time present a greater perception into an organization’s underlying efficiency.
As these metrics affect top- and bottom-line efficiency, evaluating them to the year-ago numbers and what analysts estimated helps buyers undertaking a inventory’s value efficiency extra precisely.
Right here is how Illumina carried out within the simply reported quarter by way of the metrics most generally monitored and projected by Wall Road analysts:
- Income- Product income: $939 million versus $897.71 million estimated by three analysts on common. In comparison with the year-ago quarter, this quantity represents a +1.7% change.
- Income- Service and different income: $165 million versus $173.11 million estimated by three analysts on common. In comparison with the year-ago quarter, this quantity represents a -17.1% change.
- Income- Microarrays- Devices: $5 million in comparison with the $4.20 million common estimate based mostly on two analysts. The reported quantity represents a change of -16.7% yr over yr.
- Income- Sequencing- Consumables: $698 million in comparison with the $704.07 million common estimate based mostly on two analysts. The reported quantity represents a change of +1.6% yr over yr.
- Revenues- Core Illumina- Whole product income: $939 million in comparison with the $888.09 million common estimate based mostly on two analysts. The reported quantity represents a change of +1.2% yr over yr.
- Revenues- Core Illumina- Service and different income: $165 million versus $181.45 million estimated by two analysts on common. In comparison with the year-ago quarter, this quantity represents a -2.4% change.
- Income- Microarrays- Consumables: $81 million versus the two-analyst common estimate of $66.61 million. The reported quantity represents a year-over-year change of +9.5%.
- Income- Core Illumina: $1.10 billion in comparison with the $1.07 billion common estimate based mostly on two analysts. The reported quantity represents a change of +0.6% yr over yr.
- Income- Sequencing- Devices: $155 million in comparison with the $116.03 million common estimate based mostly on two analysts. The reported quantity represents a change of -3.7% yr over yr.
View all Key Company Metrics for Illumina here>>>
Shares of Illumina have returned -10.7% over the previous month versus the Zacks S&P 500 composite’s +2.1% change. The inventory presently has a Zacks Rank #3 (Maintain), indicating that it might carry out consistent with the broader market within the close to time period.
7 Finest Shares for the Subsequent 30 Days
Simply launched: Consultants distill 7 elite shares from the present checklist of 220 Zacks Rank #1 Robust Buys. They deem these tickers “Most Doubtless for Early Worth Pops.”
Since 1988, the complete checklist has crushed the market greater than 2X over with a median achieve of +24.3% per yr. So you’ll want to give these hand picked 7 your rapid consideration.
Illumina, Inc. (ILMN) : Free Stock Analysis Report
To read this article on Zacks.com click here.
The views and opinions expressed herein are the views and opinions of the writer and don’t essentially mirror these of Nasdaq, Inc.
